Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care.


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
19 08 2021
Historique:
received: 14 06 2021
accepted: 09 08 2021
entrez: 20 8 2021
pubmed: 21 8 2021
medline: 21 10 2021
Statut: epublish

Résumé

Long-term outbreaks of multidrug-resistant Gram-negative bacilli related to hospital-building water systems have been described. However, successful mitigation strategies have rarely been reported. In particular, environmental disinfection or replacement of contaminated equipment usually failed to eradicate environmental sources of Pseudomonas aeruginosa. We report the investigation and termination of an outbreak of P. aeruginosa producing VIM carbapenemase (PA-VIM) in the adult intensive care unit (ICU) of a Swiss tertiary care hospital with active case finding, environmental sampling and whole genome sequencing (WGS) of patient and environmental strains. We also describe the implemented control strategies and their effectiveness on eradication of the environmental reservoir. Between April 2018 and September 2020, 21 patients became either infected or colonized with a PA-VIM strain. For 16 of them, an acquisition in the ICU was suspected. Among 131 environmental samples collected in the ICU, 13 grew PA-VIM in sink traps and drains. WGS confirmed the epidemiological link between clinical and environmental strains and the monoclonal pattern of the outbreak. After removing sinks from patient rooms and implementation of waterless patient care, no new acquisition was detected in the ICU within 8 months after the intervention. Implementation of waterless patient care with removal of the sinks in patient rooms was successful for termination of a PA-VIM ICU outbreak linked to multiple environmental water sources. WGS provides highly discriminatory accuracy to investigate environment-related outbreaks.

Sections du résumé

BACKGROUND
Long-term outbreaks of multidrug-resistant Gram-negative bacilli related to hospital-building water systems have been described. However, successful mitigation strategies have rarely been reported. In particular, environmental disinfection or replacement of contaminated equipment usually failed to eradicate environmental sources of Pseudomonas aeruginosa.
METHODS
We report the investigation and termination of an outbreak of P. aeruginosa producing VIM carbapenemase (PA-VIM) in the adult intensive care unit (ICU) of a Swiss tertiary care hospital with active case finding, environmental sampling and whole genome sequencing (WGS) of patient and environmental strains. We also describe the implemented control strategies and their effectiveness on eradication of the environmental reservoir.
RESULTS
Between April 2018 and September 2020, 21 patients became either infected or colonized with a PA-VIM strain. For 16 of them, an acquisition in the ICU was suspected. Among 131 environmental samples collected in the ICU, 13 grew PA-VIM in sink traps and drains. WGS confirmed the epidemiological link between clinical and environmental strains and the monoclonal pattern of the outbreak. After removing sinks from patient rooms and implementation of waterless patient care, no new acquisition was detected in the ICU within 8 months after the intervention.
DISCUSSION
Implementation of waterless patient care with removal of the sinks in patient rooms was successful for termination of a PA-VIM ICU outbreak linked to multiple environmental water sources. WGS provides highly discriminatory accuracy to investigate environment-related outbreaks.

Identifiants

pubmed: 34412676
doi: 10.1186/s13054-021-03726-y
pii: 10.1186/s13054-021-03726-y
pmc: PMC8376114
doi:

Substances chimiques

Bacterial Proteins 0
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

301

Informations de copyright

© 2021. The Author(s).

Références

Antimicrob Agents Chemother. 2014 May;58(5):2626-37
pubmed: 24550343
Intensive Care Med. 2018 Nov;44(11):1777-1786
pubmed: 30343312
Clin Infect Dis. 2017 May 15;64(10):1435-1444
pubmed: 28200000
Infect Control Hosp Epidemiol. 2009 Jan;30(1):25-33
pubmed: 19046054
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
Front Microbiol. 2020 Jul 22;11:1729
pubmed: 32793169
Curr Opin Infect Dis. 2013 Aug;26(4):345-51
pubmed: 23806897
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1463-1466
pubmed: 30526717
Diagn Microbiol Infect Dis. 2015 Aug;82(4):274-7
pubmed: 25952482
Swiss Med Wkly. 2009 Dec 26;139(51-52):747-51
pubmed: 19924582
J Clin Microbiol. 2015 Aug;53(8):2622-31
pubmed: 26041902
J Antimicrob Chemother. 2003 Jun;51(6):1409-14
pubmed: 12716773
Infect Control Hosp Epidemiol. 2004 Dec;25(12):1083-9
pubmed: 15636297
Clin Infect Dis. 2004 Aug 15;39(4):511-6
pubmed: 15356814
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1467-1469
pubmed: 30526714
Crit Care Explor. 2020 Jul 29;2(8):e0173
pubmed: 32766566
Clin Microbiol Infect. 2019 Jul;25(7):830-838
pubmed: 30616014
Pediatr Infect Dis J. 2010 Mar;29(3):233-7
pubmed: 19940801
Antimicrob Agents Chemother. 2013 Jul;57(7):3224-9
pubmed: 23629703
Clin Infect Dis. 2019 Feb 15;68(5):873-884
pubmed: 30475989
Expert Rev Anti Infect Ther. 2019 Aug;17(8):557-569
pubmed: 31313610
Infect Control Hosp Epidemiol. 2019 Jun;40(6):621-626
pubmed: 30942147
N Engl J Med. 2005 Jan 27;352(4):380-91
pubmed: 15673804
J Hosp Infect. 2016 Sep;94(1):2-7
pubmed: 27451039
Euro Surveill. 2013 Oct 17;18(42):
pubmed: 24176582
Nature. 2000 Aug 31;406(6799):959-64
pubmed: 10984043
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Am J Infect Control. 2005 Jun;33(5 Suppl 1):S26-40
pubmed: 15940114
Front Public Health. 2020 Jan 28;8:3
pubmed: 32047733
J Clin Microbiol. 2017 Sep;55(9):2858-2864
pubmed: 28701421
Clin Infect Dis. 2016 Jun 1;62(11):1423-35
pubmed: 26936670
Antimicrob Resist Infect Control. 2020 Feb 11;9(1):29
pubmed: 32046775
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1497-1498
pubmed: 30526713

Auteurs

Gaud Catho (G)

Infection Control Program, WHO Collaborating Center for Patient Safety, Faculty of Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 4, CH-1205, Geneva, Switzerland. gaud.catho@protonmail.ch.

R Martischang (R)

Infection Control Program, WHO Collaborating Center for Patient Safety, Faculty of Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 4, CH-1205, Geneva, Switzerland.

F Boroli (F)

Division of Critical Care, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

M N Chraïti (MN)

Infection Control Program, WHO Collaborating Center for Patient Safety, Faculty of Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 4, CH-1205, Geneva, Switzerland.

Y Martin (Y)

Infection Control Program, WHO Collaborating Center for Patient Safety, Faculty of Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 4, CH-1205, Geneva, Switzerland.

Z Koyluk Tomsuk (Z)

Division of Critical Care, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

G Renzi (G)

Bacteriology Laboratory, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

J Schrenzel (J)

Bacteriology Laboratory, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

J Pugin (J)

Division of Critical Care, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

P Nordmann (P)

Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.

D S Blanc (DS)

Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
Service of Hospital Preventive Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

S Harbarth (S)

Infection Control Program, WHO Collaborating Center for Patient Safety, Faculty of Medicine, Geneva University Hospitals, Rue Gabrielle Perret-Gentil, 4, CH-1205, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH